By starting with a low dose and incrementally increasing it over several weeks or months, your body has time to acclimate, which improves tolerability and helps ensure you can continue treatment effectively towards a maintenance dose
Drucker has served as an advisor or consultant within the past 12 months to Amylin Pharmaceuticals, Arisaph Pharmaceuticals, Diartis Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Merck Research Laboratories, Novo Nordisk, NPS Pharmaceuticals, Takeda and Transition Pharmaceuticals
Nonetheless, these symptoms led to discontinuation of treatment in 4-8% of patients enrolled in completed obesity trials for semaglutide (Novo Nordisk), and the dual GLP-1/GIP receptor agonist tirzepatide (Eli Lilly)
S2CID 20920554
There are some side effects, and its a personal decision whether to take it or not, one that should be discussed with your healthcare team